Pedro Martins da Silva Filho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Martins da Silva Filho has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Elisane Longhinotti
Department of Analytical Chemistry and Physical Chemistry, Federal University of Ceara, Fortaleza, Brazil
4 shared publications - Eduardo Henrique Silva Sousa
Federal University of Ceará
3 shared publications - Luiz Gonzaga de França Lopes
Federal University of Ceará
2 shared publications Alexandre S. Leitão Junior
Departament of Urology, Federal University of Ceará, 1290 Pastor Samuel Munguba St., Fortaleza - CE, 60430-372, Fortaleza, Ceará, Brazil
1 shared publicationCamila P. Aquino
Instituto Superior de Ciências Biomédicas , Universidade Estadual do Ceará , 60714-110 Fortaleza , Ceará , Brazil
1 shared publicationClaudia F. Santos
Department of Physiology and Pharmacology, Superior Institute of Biomedical Sciences, State University of Ceará, 1700. Dr Silas Munguba Av., 60455-900, Fortaleza Ceará, Brazil
1 shared publication
Latest Publications
- 22 October 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177071
Pharmacological evaluation of a new nanoformulation in the erectile tissue of rabbits and humans
- 22 October 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177071
Pharmacological evaluation of a new nanoformulation in the erectile tissue of rabbits and humans
- 1 January 2024
- Published by Sociedade Brasileira de Quimica (SBQ) in Revista Virtual de Química
- Vol. 16 (2) , 223-233
Anchoring of a Ruthenium Complex in Mesoporous Silica Via a Covalent Route
- 1 January 2024
- Published by Sociedade Brasileira de Quimica (SBQ) in Revista Virtual de Química
- Vol. 16 (2) , 223-233
Anchoring of a Ruthenium Complex in Mesoporous Silica Via a Covalent Route
- 9 November 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (1) , 6-22
Nitroprusside─Expanding the Potential Use of an Old Drug Using Nanoparticles
For more than 70 years, sodium nitroprusside (SNP) has been used to treat severe hypertension in hospital emergency settings. During this time, a few other clinical uses have also emerged such as in the treatment of acute heart failure as well as improving mitral incompetence and in the intra- and perioperative management during heart surgery. This drug functions by releasing nitric oxide (NO), which modulates several biological processes with many potential therapeutic applications. However, this small molecule has a short lifetime, and it has been administered through the use of NO donor molecules such as SNP. On the other hand, SNP also has some setbacks such as the release of cyanide ions, high water solubility, and very fast NO release kinetics. Currently, there are many drug delivery strategies that can be applied to overcome many of these limitations, providing novel opportunities for the use of old drugs, including SNP. This Perspective describes some nitroprusside properties and highlights new potential therapeutic uses arising from the use of drug delivery systems, mainly silica-based nanoparticles. There is a series of great opportunities to further explore SNP in many medical issues as reviewed, which deserves a closer look by the scientific community.
- 9 November 2022
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 20 (1) , 6-22
Nitroprusside─Expanding the Potential Use of an Old Drug Using Nanoparticles
For more than 70 years, sodium nitroprusside (SNP) has been used to treat severe hypertension in hospital emergency settings. During this time, a few other clinical uses have also emerged such as in the treatment of acute heart failure as well as improving mitral incompetence and in the intra- and perioperative management during heart surgery. This drug functions by releasing nitric oxide (NO), which modulates several biological processes with many potential therapeutic applications. However, this small molecule has a short lifetime, and it has been administered through the use of NO donor molecules such as SNP. On the other hand, SNP also has some setbacks such as the release of cyanide ions, high water solubility, and very fast NO release kinetics. Currently, there are many drug delivery strategies that can be applied to overcome many of these limitations, providing novel opportunities for the use of old drugs, including SNP. This Perspective describes some nitroprusside properties and highlights new potential therapeutic uses arising from the use of drug delivery systems, mainly silica-based nanoparticles. There is a series of great opportunities to further explore SNP in many medical issues as reviewed, which deserves a closer look by the scientific community.
- 13 May 2019
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (7) , 2912-2921
Incorporation of Nitroprusside on Silica Nanoparticles—A Strategy for Safer Use of This NO Donor in Therapy
Silica-based nanoparticles have been developed as powerful platforms for drug delivery and might also prevent undesired side effects of drugs. Here, a fast method to synthesize positively charged mesoporous silica nanoparticles (ζ = 20 ± 0.5 mV, surface area = 678 m2 g–1, and 2.3 nm of porous size) was reported. This nanomaterial was employed to anchor sodium nitroprusside (SNP), a vasodilator drug with undesired cyanide release. A remarkable incorporation of 323.9 ± 7.55 μmol of SNP per gram of nanoparticle was achieved, and a series of studies of NO release were conducted, showing efficient release of NO along with major cyanide retention (ca. 64% bound to nanoparticle). Biological assays with mammalian cells showed only a slight drop in cell viability (13%) at the highest concentration (1000 μM), while SNP exhibited an LC50 of 228 μM. Moreover, pharmacological studies demonstrated similar efficacy for vasodilation and sGC-PKG-VASP pathway activation when compared to SNP alone. Altogether, this new SNP silica nanoparticle has great potential as an alternative for wider and safer use of SNP in medicine with lower cyanide toxicity.
- 13 May 2019
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (7) , 2912-2921
Incorporation of Nitroprusside on Silica Nanoparticles—A Strategy for Safer Use of This NO Donor in Therapy
Silica-based nanoparticles have been developed as powerful platforms for drug delivery and might also prevent undesired side effects of drugs. Here, a fast method to synthesize positively charged mesoporous silica nanoparticles (ζ = 20 ± 0.5 mV, surface area = 678 m2 g–1, and 2.3 nm of porous size) was reported. This nanomaterial was employed to anchor sodium nitroprusside (SNP), a vasodilator drug with undesired cyanide release. A remarkable incorporation of 323.9 ± 7.55 μmol of SNP per gram of nanoparticle was achieved, and a series of studies of NO release were conducted, showing efficient release of NO along with major cyanide retention (ca. 64% bound to nanoparticle). Biological assays with mammalian cells showed only a slight drop in cell viability (13%) at the highest concentration (1000 μM), while SNP exhibited an LC50 of 228 μM. Moreover, pharmacological studies demonstrated similar efficacy for vasodilation and sGC-PKG-VASP pathway activation when compared to SNP alone. Altogether, this new SNP silica nanoparticle has great potential as an alternative for wider and safer use of SNP in medicine with lower cyanide toxicity.